Summary & Overview
HCPCS J7174: Fitusiran Injection, 0.04 mg
HCPCS Level II code J7174 denotes an injection of fitusiran, billed per 0.04 mg unit. Fitusiran is a specialty therapeutic agent administered by subcutaneous injection, and the code captures the drug product quantity rather than the administration procedure. National attention to this code stems from the high-cost specialty drug market and evolving coverage policies for novel hemostasis-targeting therapies. Payers use unit-based HCPCS drug codes like J7174 to adjudicate pharmacy and medical benefit claims, establish pricing, and track utilization.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks for payer coverage approaches, an outline of policy considerations affecting reimbursement and site-of-service determinations, and the clinical context for fitusiran as a subcutaneous therapeutic injection. The publication also highlights coding implications for billing teams, expected places of service for claims submission, and gaps where specific payer policies or diagnosis mappings are not publicly available.
This executive summary is intended for national audiences involved in revenue cycle, pharmacy policy, and specialty drug management who need a clear, practical reference to HCPCS Level II code J7174 and its role in billing and coverage workflows.
Billing Code Overview
HCPCS Level II code J7174 represents an injection of fitusiran, with a billing unit of 0.04 mg. This code is used for administration of the medication formulated for subcutaneous injection.
Service Type: Therapeutic injection / specialty pharmaceutical administration
Typical Site of Service: Outpatient infusion clinic, specialty clinic, or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A representative patient is an adult with hemophilia A or B with inhibitors or a rare bleeding disorder receiving prophylactic subcutaneous therapy with fitusiran. The encounter occurs in an outpatient infusion clinic, hematology specialty clinic, or physician office staffed by a hematologist, advanced practice provider, and nursing team. The clinician documents indications, consent, baseline labs (liver function tests, platelet count), and prior bleeding history. The medication J7174 (injection, fitusiran, 0.04 mg) is prepared by pharmacy under sterile technique; the nurse verifies patient identity and medication order, performs a targeted assessment, and administers a subcutaneous injection. Post‑administration monitoring includes observation for injection‑site reactions, hypersensitivity, and brief vital sign checks, with instructions for adverse event reporting and scheduling of follow‑up labs and dosing. Billing uses the HCPCS unit quantity corresponding to the administered milligram amount billed as units of J7174.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/full coverage modifier (no special circumstances) | Use when no modifier applies and full services rendered as billed |